CASI Pharmaceuticals Inc. (CASI)
CASI Pharmaceuticals Statistics
Share Statistics
CASI Pharmaceuticals has 13.4M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 13.4M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 11.14% |
| Shares Floating | 5.51M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 19.08K, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 19.08K |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.16% |
| Short Ratio (days to cover) | 1.69 |
Valuation Ratios
The PE ratio is -1.11 and the forward PE ratio is -1.13. CASI Pharmaceuticals's PEG ratio is -0.04.
| PE Ratio | -1.11 |
| Forward PE | -1.13 |
| PS Ratio | 1.52 |
| Forward PS | 0.2 |
| PB Ratio | 23.45 |
| P/FCF Ratio | -1.47 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CASI Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 11.96.
| Current Ratio | 1.09 |
| Quick Ratio | 0.94 |
| Debt / Equity | 11.96 |
| Debt / EBITDA | -0.64 |
| Debt / FCF | -0.75 |
| Interest Coverage | -45.49 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $122.48K |
| Profits Per Employee | $-168.49K |
| Employee Count | 233 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 3.31 |
Taxes
| Income Tax | 1.19M |
| Effective Tax Rate | -3.12% |
Stock Price Statistics
The stock price has increased by -18.03% in the last 52 weeks. The beta is 0.61, so CASI Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | -18.03% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 4.37 |
| Relative Strength Index (RSI) | 45.03 |
| Average Volume (20 Days) | 12.26K |
Income Statement
In the last 12 months, CASI Pharmaceuticals had revenue of 28.54M and earned -39.26M in profits. Earnings per share was -2.56.
| Revenue | 28.54M |
| Gross Profit | 11.15M |
| Operating Income | -39.62M |
| Net Income | -39.26M |
| EBITDA | -34.87M |
| EBIT | -37.2M |
| Earnings Per Share (EPS) | -2.56 |
Balance Sheet
The company has 13.47M in cash and 22.14M in debt, giving a net cash position of -8.67M.
| Cash & Cash Equivalents | 13.47M |
| Total Debt | 22.14M |
| Net Cash | -8.67M |
| Retained Earnings | -700.08M |
| Total Assets | 53.67M |
| Working Capital | 3.12M |
Cash Flow
In the last 12 months, operating cash flow was -29.22M and capital expenditures -240K, giving a free cash flow of -29.46M.
| Operating Cash Flow | -29.22M |
| Capital Expenditures | -240K |
| Free Cash Flow | -29.46M |
| FCF Per Share | -1.92 |
Margins
Gross margin is 39.06%, with operating and profit margins of -138.84% and -137.57%.
| Gross Margin | 39.06% |
| Operating Margin | -138.84% |
| Pretax Margin | -133.4% |
| Profit Margin | -137.57% |
| EBITDA Margin | -122.18% |
| EBIT Margin | -138.84% |
| FCF Margin | -103.25% |
Dividends & Yields
CASI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CASI is $4, which is 100% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 100% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jun 2, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 2, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -19.57 |
| Piotroski F-Score | 3 |